An Alzheimer's drug brought to market in one of the most controversial FDA approval processes ever-- is the subject of my cover story this week on Full Measure.
Aducanumab, now sold as Aduhelm, was introduced last June at a cost of $50,000 a year per patient.
The FDA approved it even though not one of its advisers said it was ready for market.
Since then, the controversies and investigations have continued. Critics say there is no hard evidence that Aduhelm works, and there is a high chance of serious-- even deadly-- side effects.
But drugmaker Biogen is still holding out hope it will take hold and provide help to the millions of people who have Alzheimer's. The FDA is standing by its official assessment that the drug is safe and effective.
Find out the latest in my report, "Mind Game."
We'll also head to Canada where they're asking why the US is begging Venezuela, which has a regime that's widely considered authoritarian, to pump more oil, overlooking the US homeland and our friendly neighbors to the north. Lisa Fletcher joins us with that report.
And Congress just passed a Postal Reform law to try to end the fiscal madness at the agency. But wait until you hear about a controversial pilot program the post office is trying out now. Rep. James Comer will explain.
How to watch? See below!
We never waste your time rehashing the same news you've heard all week. Find out how to watch on TV, online or on demand by clicking this link: How to Watch Full Measure